Theratechnologies Actions en circulation
Quel est le Actions en circulation de Theratechnologies?
Le Actions en circulation de Theratechnologies Inc. est 45.981M
Quelle est la définition de Actions en circulation?
Les actions en circulation sont toutes les actions d'une société ou d'un actif financier qui ont été autorisées, émises et achetées par les investisseurs et qui sont détenues par eux.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Actions en circulation des entreprises dans Health Care secteur sur NASDAQ par rapport à Theratechnologies
Que fait Theratechnologies?
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
Entreprises avec actions en circulation similaire à Theratechnologies
- Tintina Mines a Actions en circulation de 45.905M
- Gensight Biologics SA a Actions en circulation de 45.920M
- NUGL a Actions en circulation de 45.923M
- Avanos Medical Inc a Actions en circulation de 45.949M
- International General Insurance Ltd a Actions en circulation de 45.954M
- Aberdeen Emerging Markets Investment Co a Actions en circulation de 45.965M
- Theratechnologies a Actions en circulation de 45.981M
- Omnicell a Actions en circulation de 45.994M
- Marathon Nextgen Realty a Actions en circulation de 46.000M
- Marathon Nextgen Realty a Actions en circulation de 46.000M
- Vesper Healthcare Acquisition a Actions en circulation de 46.000M
- The Allstate a Actions en circulation de 46.000M
- Social Capital Hedosophia IV a Actions en circulation de 46.000M